TargetMol

Pegamotecan

Product Code:
 
TAR-T24610
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T24610-1mg1mg£384.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T24610-5mg5mg£816.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T24610-10mg10mg£1,083.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T24610-25mg25mg£1,581.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T24610-50mg50mg£2,103.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Pegamotecan is an inhibitor of Topoisomerase-I. It was used as a treatment of Gastric and Gastroesophageal Junction Adenocarcinoma.
CAS:
581079-18-7
Formula:
C52H48N6O14
Molecular Weight:
980.984
Pathway:
DNA Damage/DNA Repair
Purity:
0.98
SMILES:
CC[C@@]1(OC(=O)[C@H](C)NC(=O)COCCOCC(=O)N[C@@H](C)C(=O)O[C@]2(CC)C(=O)OCc3c2cc2-c4nc5ccccc5cc4Cn2c3=O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O
Target:
Topoisomerase

References

1. Chuang CH, Wu PC, Tsai TH, Fang YP, Tsai YH, Cheng TC, Huang CC, Huang MY, Chen FM, Hsieh YC, Lin WW, Tsai MJ, Cheng TL. Development of pH-Sensitive Cationic PEGylated Solid Lipid Nanoparticles for Selective Cancer-Targeted Therapy. J Biomed Nanotechnol. 2017 Feb;13(2):192-03. PubMed PMID: 29377649. 2. Omar R, Bardoogo YL, Corem-Salkmon E, Mizrahi B. Amphiphilic star PEG-Camptothecin conjugates for intracellular targeting. J Control Release. 2017 Jul 10;257:76-83. doi: 10.1016/j.jconrel.2016.09.025. Epub 2016 Sep 24. PubMed PMID: 27677603. 3. Song ZL, Chen HL, Wang YH, Goto M, Gao WJ, Cheng PL, Morris-Natschke SL, Liu YQ, Zhu GX, Wang MJ, Lee KH. Design and synthesis of novel PEG-conjugated 20(S)-camptothecin sulfonylamidine derivatives with potent in vitro antitumor activity via Cu-catalyzed three-component reaction. Bioorg Med Chem Lett. 2015 Jul 1;25(13):2690-3. doi: 10.1016/j.bmcl.2015.04.060. Epub 2015 May 6. PubMed PMID: 25987370; PubMed Central PMCID: PMC4768722. 4. Scott LC, Yao JC, Benson AB 3rd, Thomas AL, Falk S, Mena RR, Picus J, Wright J, Mulcahy MF, Ajani JA, Evans TR. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother Pharmacol. 2009 Jan;63(2):363-70. doi: 10.1007/s00280-008-0746-2. Epub 2008 Apr 9. PubMed PMID: 18398613.